Cascades Reports Third Quarter 2026 Results

Cascades delivered higher Q3 sales and earnings, but warns of tougher conditions ahead.

What the company is saying

Cascades Inc. reports Q3 2026 results as meeting internal expectations despite ongoing headwinds from tariffs, cost inflation, and economic uncertainty. The company highlights a 2% year-over-year sales increase to $1,267 million and improved operating income of $78 million. CEO Hugues Simon emphasizes that the Packaging segment was pressured by $4 million in tariff impacts and higher input costs, while the Tissue segment outperformed internal forecasts due to price increases and cost controls. Management frames the quarter as one of disciplined execution, citing progress on asset sales and a stable financial position. The company reiterates its commitment to capital discipline, productivity, and long-term competitiveness, but tempers optimism by forecasting slightly lower Q4 results and continued cost pressures.

What the data suggests

The numbers show Q3 2026 sales of $1,267 million, up from $1,238 million in Q3 2025 and $1,219 million in Q2 2026. Operating income rose to $78 million from $73 million a year ago and $58 million last quarter. Net earnings per share reached $0.30, marginally above last year's $0.29. Adjusted EBITDA (A) was $162 million, up from $159 million year-over-year, with an EBITDA margin steady at 12.8%. Net debt declined to $1,863 million, improving the net debt to EBITDA (A) ratio to 3.2x from 3.3x last quarter. Capital expenditures increased to $47 million, and asset sale proceeds for the year-to-date reached $165 million, with a $230 million target now expected in early 2027. Segment data reveals Packaging Products generated $807 million in sales and $64 million in operating income, while Tissue Papers delivered $415 million in sales and $32 million in operating income. The company absorbed $7 million in impairments, $3 million in environmental costs, and $4 million in restructuring charges, partially offset by $8 million in real estate gains and $1 million from an investment sale. The dividend is set at $0.12 per share for December 2026. Management’s qualitative claims about 'exceeding expectations' in Tissue and 'better than anticipated' corporate performance are not directly quantified, but the overall financial trajectory is positive.

Analysis

The announcement provides a comprehensive and balanced disclosure of Cascades Inc.'s Q3 2026 financial results, with realised figures for sales, operating income, net earnings, EBITDA, and segment performance. The majority of claims are factual and supported by numerical data, including sequential and year-over-year improvements in key profitability metrics. Forward-looking statements are limited and appropriately caveated, focusing on the ongoing asset sale program and management's expectation for slightly lower Q4 results. There is no evidence of exaggerated or promotional language; qualitative statements about exceeding expectations or improved contributions are not materially overstated and do not dominate the narrative. Capital expenditures are disclosed and in line with ongoing operations, with no indication of a large, speculative outlay paired with uncertain long-term returns. The tone remains measured, and the gap between narrative and evidence is minimal.

Risk flags

• ●Cost inflation and tariffs remain significant risks, with the Packaging segment facing $4 million in tariff impacts this quarter and ongoing exposure to volatile raw material and transportation costs. These pressures could erode margins if not offset by further price increases or cost controls.
• ●Volume declines, particularly in the Tissue segment's Away-from-Home business, contributed to a $50 million negative volume impact year-over-year. If demand remains uneven or weak, revenue growth could stall despite pricing actions.
• ●The asset sale program, while progressing, has not yet reached its $230 million target. Any delays or shortfalls in asset disposals could affect the company’s ability to reduce debt and fund capital expenditures as planned.
• ●Management’s outlook for Q4 is cautious, anticipating sequentially lower results due to persistent cost and demand headwinds. This signals limited near-term earnings upside and ongoing operational challenges.
• ●The company’s high net debt level ($1,863 million) and a net debt to EBITDA (A) ratio of 3.2x leave limited room for error if market conditions deteriorate or if asset sales underperform expectations.

Bottom line

Cascades Inc. delivered modest year-over-year and sequential improvements in sales, operating income, and adjusted EBITDA for Q3 2026, while making progress on debt reduction and asset sales. The company is managing through a challenging environment marked by cost inflation, tariff impacts, and uneven demand, with management signaling that Q4 will likely see a slight dip in results. The $230 million asset sale target remains a key milestone, with $165 million already realized and completion expected in early 2027. Dividend continuity at $0.12 per share provides some income stability. Investors should focus on the company’s ability to offset cost pressures, execute on asset sales, and maintain financial flexibility amid persistent macro headwinds. The most important takeaway is that while Cascades is executing well operationally, external risks and a cautious near-term outlook limit the scope for upside in the coming quarter.

Announcement summary

(TSX: CAS) Cascades Inc. reported unaudited financial results for the three-month period ended September 30, 2026. Sales for Q3 2026 were $1,267 million, compared with $1,219 million in Q2 2026 and $1,238 million in Q3 2025. Operating income was $78 million, up from $58 million in Q2 2026 and $73 million in Q3 2025. Net earnings per common share were $0.30, compared to $0.21 in Q2 2026 and $0.29 in Q3 2025. Adjusted EBITDA (A) was $162 million, compared to $140 million in Q2 2026 and $159 million in Q3 2025. Adjusted net earnings per common share were $0.33, compared to $0.24 in Q2 2026 and $0.38 in Q3 2025. Net debt as of September 30, 2026 was $1,863 million, down from $1,879 million as of June 30, 2026. The net debt to EBITDA (A) ratio was 3.2x, down from 3.3x as of June 30, 2026. Total capital expenditures in Q3 2026 were $47 million, compared to $40 million in Q2 2026 and $30 million in Q3 2025. The 2026 forecasted capital expenditures before disposals are expected to be in a range of $150 million to $175 million. The company generated $11 million in asset sale proceeds during Q3 2026, bringing total proceeds to $165 million for the 2025-2026 period. The objective of generating $230 million in asset sale proceeds is progressing well and is now expected to be achieved in early 2027. Segmented sales in Q3 2026 were $807 million for Packaging Products, $415 million for Tissue Papers, and $45 million for Inter-segment sales, Corporate, Recovery and Recycling activities. Segmented operating income in Q3 2026 was $64 million for Packaging Products, $32 million for Tissue Papers, and a loss of $18 million for Corporate, Recovery and Recycling activities. Segmented EBITDA (A) in Q3 2026 was $126 million for Packaging Products, $47 million for Tissue Papers, and a loss of $11 million for Corporate, Recovery and Recycling activities. The company reported a $7 million impairment on equipment related to a discontinued product line and a recovery facility in Canada, $8 million of gains from the sale of real estate from a closed recovery facility in Canada, $3 million of environmental costs related to a previously closed plant in the United States, $4 million of restructuring costs related to a previously closed plant in the United States and corporate organizational changes, and $1 million of gains from the sale of an investment in a non-significant associate. The Board of Directors declared a quarterly dividend of $0.12 per common share to be paid on December 3, 2026 to shareholders of record at the close of business on November 19, 2026. During Q3 2026, Cascades purchased no common shares for cancellation. Hugues Simon, President and CEO, stated that third quarter results were in line with expectations despite headwinds from tariff-related disruptions, cost inflation, and economic uncertainty. The Packaging segment faced higher raw material and transportation costs and tariff impacts of approximately $4 million. The Tissue segment results exceeded expectations, with selling price increases offsetting inflationary pressures and lower volume in the Away-from-Home business. Corporate activities performed better than anticipated due to cost reduction initiatives and improved contribution from Recovery and Recycling operations. The company remains focused on disciplined capital management, productivity, customer portfolio optimization, and initiatives to strengthen long-term resilience and competitiveness. Management expects consolidated fourth quarter results to be slightly lower sequentially, with continued pressure from raw material costs, transportation expenses, and tariff-related impacts, but ongoing price increases and profitability improvement initiatives are expected to help mitigate these pressures.

Disagree with this article?